Drug Trial Radar · NCT02546700
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
309
Actual
Start
Sep 17, 2015
Primary completion
Nov 25, 2016
Study completion Nov 25, 2016
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 11, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one long-acting bronchodilator inhaler medication. This study will be conducted to assess the safety, efficacy, and patient-reported outcome (PRO) measures.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
LebrikizumabDrug
Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
PlaceboDrug
Matching placebo will be administered subcutaneously once in every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12Time frame: Baseline, Week 12
Locations
63 sites in 9 countries. Site status is shown where the registry gives one.
Achieve Clinical Research, LLC
Birmingham, Alabama
California Medical Research Associates, Inc.
Northridge, California
Palmtree Clinical research Inc
Palm Springs, California
Finlay Medical Research
Miami, Florida
Progressive Medical Research
Port Orange, Florida
Columbus Regional Research Institute
Columbus, Georgia
Southeast Regional Res Group
Savannah, Georgia
Centex Studies
Lake Charles, Louisiana
The Clinical Research Ctr
St Louis, Missouri
Comprehensive Clinical Research Inc.
Berlin, New Jersey
ISA Clinical Research
Jamaica, New York
Gastonia Pharmaceutical Research
Gastonia, North Carolina
Clinical Research Inst. of Southern Oregon, Pc
Medford, Oregon
S. Carolina Pharmaceutical Research
Spartanburg, South Carolina
Baylor College of Medicine; Ben Taub Hospital- Guntupalli
Houston, Texas
Centex Studies
Houston, Texas
Western Washington Medical Group
Everett, Washington
Premier Clinical Research
Spokane, Washington
MultiCare Health Center of Washington
Tacoma, Washington
Centro Médico Dra de Salvo
Buenos Aires, Argentina
Instituto Ave Pulmo
Mar del Plata, Argentina
Centro Respiratorio Quilmes
Quilmes, Argentina
Investigaciones en Patologias Respiratorias
San Miguel de Tucumán, Argentina
Instituto Del Buen Aire
Santa Fe, Argentina
Specialized Hospital For Active Treatment of Pneumophthisiatric Diseases; Dept of Pneumonology
Rousse, Bulgaria
MHC - Sofia, EOOD
Sofia, Bulgaria
Fifth MHAT - Sofia EAD
Sofia, Bulgaria
National Multiprofile Transport Hospital Tzar Boris Ill; Clinic of Internal Diseases
Sofia, Bulgaria
Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
Stara Zagora, Bulgaria
Medical Center Tara OOD
Veliko Tarnovo, Bulgaria
McMaster University Medical Centre
Hamilton, Ontario, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Inspiration Research
Toronto, Ontario, Canada
Hvidovre Hospital, Lungemedicinsk Afdeling
Hvidovre, Denmark
Lungemedicinsk afd. L, Bispebjerg Hospital
København NV, Denmark
Odense Universitetshospital, Lungemedicinsk Forskningsenhed
Odense C, Denmark
Dr. Kenessey Albert Korhaz Es Rendelointezet; Tudoosztaly (Pulmonolgy Dept )
Balassagyarmat, Hungary
Petz Aladar Megyei Oktato Korhaz
Győr, Hungary
Selye János Kórház és Rendel?intézet; Allergológiai Szakrendelés
Komárom, Hungary
Matrai Állami Gyógyintézet ; Bronchológia
Mátraháza, Hungary
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.